论文部分内容阅读
目的探讨错配修复基因hMSH2在乳腺浸润性导管癌和癌前病变中的表达及与临床病理指标的关系。方法采用免疫组化EnVision法检测75例乳腺浸润性导管癌、20例癌前病变(导管内乳头状瘤病13例,导管上皮不典型增生7例)及30例正常乳腺组织中hMSH2蛋白的表达情况。结果乳腺浸润性导管癌和癌前病变与正常乳腺组织相比hMSH2蛋白表达阳性率均明显降低,分别为72%和80%(P<0.05)。hMSH2在乳腺癌中的表达率低于癌前病变组,但两者差异无统计学意义(P>0.05)。乳腺癌中hMSH2表达降低与肿瘤体积大、组织分化差和腋窝淋巴结转移有关(P<0.05),与患者年龄、临床分期及C-erbB-2、ER、PR表达无关(P>0.05)。结论错配修复蛋白hMSH2表达缺陷是乳腺癌多步骤发展过程的早期事件,在进展阶段与乳腺癌的低分化和转移关系密切。
Objective To investigate the expression of mismatch repair gene hMSH2 in infiltrating ductal carcinoma and precancerous lesions and its relationship with clinicopathological parameters. Methods Immunohistochemical EnVision method was used to detect the expression of hMSH2 protein in 75 cases of breast invasive ductal carcinoma, 20 cases of precancerous lesion (13 cases of intraductal papillomatosis, 7 cases of ductal atypical hyperplasia) and 30 cases of normal breast tissue Happening. Results The positive rates of hMSH2 protein in breast invasive ductal carcinoma and precancerous lesions were significantly lower than those in normal breast tissue (72% and 80%, respectively, P <0.05). The expression of hMSH2 in breast cancer was lower than that in precancerous lesions, but there was no significant difference between them (P> 0.05). The decrease of hMSH2 expression in breast cancer was related to tumor volume, poor tissue differentiation and axillary lymph node metastasis (P <0.05), but not related to age, clinical stage and the expression of C-erbB-2, ER and PR. Conclusion Mismatch repair protein hMSH2 expression is an early event in the multi-step development of breast cancer. It is closely related to the poor differentiation and metastasis of breast cancer in the progression stage.